Author:
Meißner Anna-Katharina,von Spreckelsen Niklas,Al Shughri Abdulkader,Brunn Anna,Fuertjes Gina,Schlamann Marc,Schmidt Matthias,Dietlein Markus,Rueß Daniel,Ruge Maximilian I.,Galldiks Norbert,Goldbrunner Roland
Abstract
Currently, contrast-enhanced MRI is the method of choice for treatment planning and follow-up in patients with meningioma. However, positron emission tomography (PET) imaging of somatostatin receptor subtype 2 (SSTR2) expression using 68Ga-DOTATATE may provide a higher sensitivity for meningioma detection, especially in cases with complex anatomy or in the recurrent setting. Here, we report on a patient with a multilocal recurrent atypical meningioma, in which 68Ga-DOTATATE PET was considerably helpful for treatment guidance and decision-making.
Reference24 articles.
1. Sstr-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery;Dijkstra;Acta Neurochir (Wien),2018
2. Expression of somatostatin receptors (Sstr1-Sstr5) in meningiomas and its clinicopathological significance;Silva;Int J Clin Exp Pathol,2015
3. Sstr2 is a prognostic factor and a promising therapeutic target in glioma;He;Am J Transl Res,2021
4. Toward radioguided surgery with B- decays: Uptake of a somatostatin analogue, dotatoc, in meningioma and high-grade glioma;Collamati;J Nucl Med,2015
5. Neuroendocrine tumor diagnosis and management: 68ga-dotatate Pet/Ct;Sanli;Ajr Am J Roentgenol,2018